Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.76 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.76 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.76 |
| ▸ | NOS1 | P29475 | 13/20 | 0.65 |
| ▸ | NOS3 | P29474 | 13/20 | 0.65 |
| ▸ | NOS2 | P35228 | 4/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | ACR | P10323 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858736 | 0.86 | SLC22A2 (1.00) | SLC22A2SLC22A1SLC22A3PRSS1ACR | |
| SCHEMBL19038559 | 0.79 | SLC22A2 (0.71) | SLC22A2SLC22A1SLC22A3PRSS1ACR | |
| SCHEMBL4983449 | 0.77 | SIGMAR1 (0.66) | SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL4980439 | 0.75 | SLC22A2 (0.59) | SLC22A2SLC22A1SLC22A3NOS1NOS3 | |
| SCHEMBL12974549 | 0.74 | SLC22A2 (0.53) | SLC22A2SLC22A1SLC22A3NOS1NOS3 | |
| SCHEMBL6183452 | 0.72 | SLC22A2 (0.57) | SLC22A2SLC22A1SLC22A3PRSS1ACR | |
| SCHEMBL742186 | 0.72 | SLC22A2 (0.56) | SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL25564920 | 0.72 | SLC22A2 (0.56) | SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL28652450 | 0.72 | SLC22A2 (0.56) | SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL13632763 | 0.72 | SLC22A2 (0.56) | SLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266828-B2 | Inhibitors of Furin and other pro-protein convertases | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150073054-A1 | INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2015-03-12 | — | — | US | disclosed |
| US-20150051138-A1 | INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051138-A1 | INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES | FURIN, PREP, PCSK6 | SLC22A2 4358/4885SLC22A1 4121/4885SLC22A3 4027/4885 |
| US-20150073054-A1 | INHIBITORS OF FURIN AND OTHER PRO-PROTEIN CONVERTASES | FURIN, PREP, PCSK6 | SLC22A2 4358/4885SLC22A1 4121/4885SLC22A3 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.